1.49
+0.145(+10.82%)
Currency In USD
| Previous Close | 1.34 |
| Open | 1.41 |
| Day High | 1.5 |
| Day Low | 1.41 |
| 52-Week High | 4.1 |
| 52-Week Low | 0.96 |
| Volume | 88,378 |
| Average Volume | 101,259 |
| Market Cap | 4.67M |
| PE | -0.26 |
| EPS | -5.63 |
| Moving Average 50 Days | 2.4 |
| Moving Average 200 Days | 2.49 |
| Change | 0.14 |
If you invested $1000 in GT Biopharma, Inc. (GTBP) since IPO date, it would be worth $1.75 as of August 18, 2025 at a share price of $1.485. Whereas If you bought $1000 worth of GT Biopharma, Inc. (GTBP) shares 5 years ago, it would be worth $17.65 as of August 18, 2025 at a share price of $1.485.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GT Biopharma Reports Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Aug 14, 2025 8:05 PM GMT
GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study;
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GlobeNewswire Inc.
Aug 11, 2025 11:00 AM GMT
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe company plans on releasing initial Phase 1 res
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
GlobeNewswire Inc.
May 19, 2025 1:00 PM GMT
Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results from Phase 1 later in 2025 following completion o